Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Cancer Lett. 2016 Nov 1;382(1):86-94. doi: 10.1016/j.canlet.2016.01.049. Epub 2016 Feb 2.
Personalised strategies in cancer care are required to overcome the therapeutic challenges posed by variability between patients and disease subsets. To this end, enhanced precision tools must be developed to describe the molecular drivers of malignant proliferation. Such tools must also identify druggable targets and biomarkers in order to provide essential information regarding drug development and therapeutic outcome. Here we discuss how proteomics-based approaches provide a set of viable methodologies capable of delivering quantitative information throughout the main stages of personalised oncology and a ratiometric platform that delivers systems-wide methods for drug evaluation.
在癌症治疗中需要个性化策略来克服患者和疾病亚群之间的治疗挑战。为此，必须开发增强的精确工具来描述恶性增殖的分子驱动因素。这些工具还必须确定可用药靶标和生物标志物，以便为药物开发和治疗结果提供必要的信息。在这里，我们讨论了基于蛋白质组学的方法如何提供一系列可行的方法，能够在个性化肿瘤学的主要阶段提供定量信息，以及提供用于药物评估的系统范围方法的比率平台。
